| |
Covariates
|
Levels
|
Adjusted OR (95 % CI)
|
p value*
|
AuROC (95 % CI) with biomarker
|
AuROC (95 % CI) without biomarker
|
p value**
|
|---|
|
Risk factors for acute kidney injurya
|
|
Model I
|
Witnessed CAc
|
No/yes
|
2.27 (0.85–6.07)
|
0.104
|
0.747 (0.667-0.817)
|
0.719 (0.649-0.790)
|
0.084
|
|
(n = 195)
|
SOFA score day 0
|
≥/<10
|
3.08 (1.46–6.48)
|
0.003
| | | |
|
Urea day 0
|
≥/<6.7 mmol/L
|
2.63 (1.40–4.95)
|
0.003
| | | |
|
Admission cystatin C
|
≥/<291/ng/mL
|
2.42 (2.29–4.54)
|
0.006
| | | |
|
Model II
|
Witnessed CAc
|
No/yes
|
2.15 (0.80–5.77)
|
0.128
|
0.752 (0.682-0.821)
|
0.719 (0.649-0.790
|
0.046
|
|
(n = 195)
|
SOFA score day 0
|
≥/<10
|
2.94 (1.39–6.21)
|
0.005
| | | |
|
Urea day 0
|
≥/<6.7 mmol/L
|
2.63 (1.40–4.95)
|
0.003
| | | |
|
Admission NGAL
|
≥/<219 ng/mL
|
2.59 (1.37–4.89)
|
0.004
| | | |
|
Model III
|
SOFA score day 0
|
≥/<10
|
2.76 (1.25–6.10)
|
0.012
|
0.725 (0.644-0.806)
| | |
|
(n = 164)
|
Urea day 0
|
≥/<6.7 mmol/L
|
1.98 (1.00–3.93)
|
0.049
| | | |
|
Cystatin C day 3
|
≥/<59 ng/mL
|
2.87 (1.45–5.70)
|
0.003
| | | |
|
Model IV
|
SOFA score day 0
|
≥/<10
|
2.83 (1.24–6.50)
|
0.014
|
0.774 (0.700-0.848)
| | |
|
(n = 164)
|
Urea day 0
|
≥/<6.7 mmol/L
|
2.82 (1.12–4.66)
|
0.024
| | | |
|
NGAL day 3
|
≥/<110 ng/mL
|
5.46 (2.65–11.24)
|
<0.001
| | | |
|
Risk factors for mortalitya
|
|
Model V
|
Initial VT/VFc
|
No/yes
|
4.70 (2.27–9.74)
|
<0.001
|
0.811 (0.751-0.872)
|
0.790 (0.727-0.852)
|
0.141
|
|
(n = 195)
|
AKI within 3 days
|
Yes/no
|
2.83 (1.40–5.69)
|
0.004
| | | |
|
SOFA sore day 0
|
≥/<10
|
3.40 (1.47–7.88)
|
0.004
| | | |
|
Admission cystatin C
|
≥/<291 ng/mL
|
2.88 (1.44–5.77)
|
0.003
| | | |
|
Model VI
|
Initial VT/VFc
|
No/yes
|
4.11 (1.99–8.53)
|
<0.001
|
0.812 (0.751-0.873)
|
0.790 (0.727-0.852)
|
0.131
|
|
(n = 195)
|
AKI within 3 days
|
Yes/no
|
2.86 (1.43–5.74)
|
0.003
| | | |
|
SOFA sore day 0
|
≥/<10
|
3.28 (1.43–7.50)
|
0.005
| | | |
|
Admission NGAL
|
≥/<219 ng/mL
|
2.87 (1.44–5.72)
|
0.003
| | | |
|
Model VII
|
Initial VT/VFc
|
No/yes
|
3.13 (1.45–6.72)
|
0.004
|
0.784 (0.713-0.854)
| | |
|
(n = 164)
|
AKI within 3 days
|
Yes/no
|
2.44 (1.16–5.13)
|
0.019
| | | |
|
SOFA sore day 0
|
≥/<10
|
2.67 (1.14–6.23)
|
0.024
| | | |
|
Cystatin C day 3
|
≥/<59 ng/mL
|
2.45 (1.17–5.13)
|
0.018
| | | |
|
Model VIII
|
Initial VT/VFc
|
No/yes
|
3.12 (1.45–6.69)
|
0.004
|
0.785 (0.713-0.857)
| | |
|
(n = 164)
|
AKI within 3 days
|
Yes/no
|
2.06 (0.95–4.47)
|
0.069
| | | |
|
SOFA score day 0
|
≥/<10
|
2.88 (1.22–6.84)
|
0.016
| | | |
|
NGAL day 3
|
≥/<110 ng/mL
|
2.85 (1.32–6.14)
|
0.008
| | | |
|
Risk factors for unfavourable neurological outcomea
|
|
Model IX
|
Initial VT/VFc
|
No/yes
|
5.07 (2.40–10.74)
|
<0.001
|
0.819 (0.759-0.878)
|
0.810 (0.750-0.870)
|
0.264
|
|
(n = 195)
|
AKI within 3 days
|
Yes/no
|
2.67 (1.32–5.40)
|
0.006
| | | |
|
BE day 0
|
</≥–7 mmol/L
|
2.07 (1.00–4.26)
|
0.050
| | | |
|
SOFA score day 0
|
≥/<10
|
2.45 (1.08–5.57)
|
0.032
| | | |
|
Admission cystatin C
|
≥/<291 ng/mL
|
2.06 (1.00–4.25)
|
0.050
| | | |
|
Model Xb
|
Initial VT/VFc
|
No/yes
|
4.92 (2.35–10.38)
|
<0.001
| |
0.810 (0.750-0.871)
| |
|
(n = 195)
|
AKI within 3 days
|
Yes/no
|
3.03 (1.52–6.02)
|
0.002
| | | |
|
BE day 0
|
</≥–7 mmol/L
|
2.56 (1.29–5.09)
|
0.007
| | | |
|
SOFA score day 0
|
≥/<10
|
2.48 (1.11–5.54)
|
0.027
| | | |
|
Model XI
|
Initial VT/VFc
|
No/yes
|
3.42 (1.58–7.39)
|
0.002
|
0.778 (0.707-0.849)
| | |
|
(n = 164)
|
AKI within 3 days
|
Yes/no
|
2.45 (1.17–5.12)
|
0.017
| | | |
|
BE day 0
|
</≥–7 mmol/L
|
2.53 (1.24–5.18)
|
0.011
| | | |
|
Cystatin C day 3
|
≥/<59 ng/mL
|
2.25 (1.09–4.65)
|
0.029
| | | |
|
Model XII
|
Initial VT/VFc
|
No/yes
|
3.77 (1.69–8.38)
|
0.001
|
0.797 (0.729-0.866)
| | |
|
(n = 164)
|
Fluid balance day 0
|
≥/<4.45 L/day
|
2.12 (1.05–4.66)
|
0.037
| | | |
|
Urea day 0
|
≥/<6.7 mmol/L
|
2.13 (1.03–4.43)
|
0.043
| | | |
|
BE day 0
|
</≥–7 mmol/L
|
2.21 (1.06–4.62)
|
0.035
| | | |
|
NGAL day 3
|
≥/<110 ng/mL
|
3.41 (1.65–7.06)
|
0.001
| | | |
-
aTIMP-2 × IGFBP7 had p values above 0.05 for predicting acute kidney injury, mortality, and unfavorable neurological outcome at all time points
-
bNGAL at day 0 had a p value above 0.05 for predicting poor neurological outcome
-
cData from some patients are missing
- Data are from multivariate logistic regression analysis
- *p values for the adjusted odds ratio; **p values from comparing the AuROC with and without biomarkers
-
OR odds ratio, CI confidence interval, AuROC area under the curve in receiver operating characteristics analysis, CA cardiac arrest, SOFA sequential organ failure assessment, NGAL neutrophil gelatinase-associated lipocalin, VF/VT ventricular fibrillation/ventricular tachycardia, AKI acute kidney injury, BE base excess
